Sarepta Therapeutics Inc (SRPT) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Return on Equity, Quarterly Results, Trends, Rankings, Statistics
What is ROE for Sarepta Therapeutics Inc in the second quarter 2026?
Sarepta Therapeutics Inc recorded a cumulative net loss of $-137 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -9.96%.
Within the Major Pharmaceutical Preparations industry 79 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1950 to 1988.
Sarepta Therapeutics: Anticipating a Turnaround Amidst Financial Challenges CAMBRIDGE, Mass. Barricading the turbulent tides of fiscal challenges, Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine, is poised to unveil its second quarter 2025 financial results. The announcement is slotted for release following the closure of the Nasdaq Global Market on Wednesday, August 6, 2025. At the heart of Sarepta’s commitment lies an urgent mission: to engineer precision genetic therapies targeting rare and devastating diseases. Yet, this noble pursuit has seen the company grappling with significant financial constraints. Sarepta Therapeutics recorded a cumulative net loss of $248 million over the 12 months ending in the first quarter of 2025, reflecting a negative return on equity (ROE) of -20%. Within the expansive Major Pharmaceutical Preparations industry, 80 peers have surpassed this return, an indicator of the uphill battle Sarepta faces in the industry landscape.The company s overall ranking on the return on equity front has notably deteriorated, plummeting from 644 to 2594 in comparison to the fourth quarter of 2024. This downward trajectory underscores the myriad obstacles Sarepta encounters amidst its path of innovation.
In the world of biopharmaceuticals, the intersection of innovative therapies and robust financial health is critical for sustained growth and development. Recent developments at Sarepta Therapeutics, a leader in precision genetic medicine, particularly in the treatment of rare diseases such as Duchenne muscular dystrophy (Duchenne), present a complex narrative that both captivates the industry and raises significant concerns. ELEVIDYS Under Investigation On a significant note, Sarepta Therapeutics issued a statement clarifying the situation surrounding its gene therapy product, ELEVIDYS (delandistrogene moxeparvovec). The announcement follows a press release from the U.S. Food and Drug Administration (FDA) regarding an investigation into the death of an eight-year-old Duchenne patient who had received the therapy. Although the FDA has specified that the death was deemed unrelated to the therapy, the implications of such an investigation can ripple through both stakeholder confidence and regulatory scrutiny.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has demonstrated substantial financial and strategic growth in the third quarter of 2024. This article analyzes the recent equity awards, revenue achievements, and market share trends of Sarepta, showcasing the company s impressive performance compared to its competitors. 1. Sarepta Therapeutics, Inc. based in Cambridge, Massachusetts, continues to make significant strides in the pharmaceutical industry, particularly in the realm of precision genetic medicine for rare diseases. The company s strategic initiatives and financial performance for the third quarter of 2024 highlight its leading position in the competitive landscape.
Sarepta Therapeutics Executes Inducement Grants for Strategic Talent Acquisition Under Nasdaq Rule 5635(c)(4) In a strategic move aimed at fortifying its competitive edge in the rapidly evolving field of precision genetic medicine for rare diseases, Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has announced significant equity awards as part of its 2024 Employment Commencement Incentive Plan. The grants, sanctioned by the Compensation Committee of the Board of Directors, are designed to attract top-tier talent crucial to the company s innovative s and long-term growth.On December 31, 2024, Sarepta granted equity awards to eight individuals who joined the company during December, a vital endeavor in a sector characterized by the necessity of highly specialized skills and expertise. This followed a previous round of inducement grants on October 31, 2024, whereby equity awards were extended to 15 new hires, aligning with the company’s commitment to fostering an environment that not only recognizes but incentivizes exceptional talent in the field of genetic medicine.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
